An open-label, randomized study of Velcade/melphalan/prednisone versus melphalan/prednisone in subjects with previously untreated multiple myeloma

Trial Profile

An open-label, randomized study of Velcade/melphalan/prednisone versus melphalan/prednisone in subjects with previously untreated multiple myeloma

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Bortezomib (Primary) ; Melphalan; Prednisone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms VISTA
  • Sponsors Millennium
  • Most Recent Events

    • 10 Dec 2013 Results for the effects of cumulative bortezomib dose on outcomes presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
    • 09 Dec 2013 Additional results were presented at the 55th Annual Meeting and Exposition of the American Society of Hematology (ASH-2013).
    • 12 Dec 2011 Results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology, according to a Janssen-Cilag media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top